0版毒性评定标准评估不良反应。按RECIST 1.0版标准进疗效评估。【结果】共入组30例晚期肿瘤患者。XC302连续给药常见的不良反应包括白细胞减少(23.3%)、血红蛋白下降(30%)、恶心(20%)、谷丙转氨酶(ALT)升高(63.3%)及谷草转氨酶升高(AST)(50%)、碱性磷酸酶升高(ALP)(23.3%)和谷氨酰转肽酶升高(GGT)(26.7%)。DLT为可逆的3度ALT和AST升高。MTD为100 mg每天一次(空腹)及75 mg qd(餐后)。23例患者进行了疗效评价,12例(52.5%)达到稳定(SD)。有1例软组织肉瘤患者无进展生存期(PFS)长达64周。【结论】PI3K抑制剂XC302连续口服给药总体耐受性良好且治疗晚期实体肿瘤有较高的疾病控制率,值得进一步研究。
目的改进pictilisib的合成工艺。方法以3-氨基-2-噻吩甲酸甲酯为起始原料,经环合、氯代、取代、甲酰化,制得2-氯-4-(吗啉-4-基)噻吩并[3,2-d]嘧啶-6-甲醛,再经还原、氯代、缩合制得关键中间体2-氯-6-[(4-甲磺酰哌嗪-1-基)甲基]-4-(吗啉-4-基)噻吩并[3,2-d]嘧啶,该中间体与2-(四氢-2H-吡喃-2-基)-4-(4,4,5,5-四甲基-[1,3,2]-二氧杂硼环戊烷-2-基)-2H-吲唑经Suzuki偶联、脱保护成盐、碱化得到目标化合物。结果与结论目标化合物结构经1H-NMR、13C-NMR、IR及MS谱确证,总收率为34.2%(以3-氨基-2-噻吩甲酸甲酯计)。与文献报道的工艺相比,该路线操作简单、条件温和、收率较高,适用于工业化生产。
近年来,乳腺癌的分子靶向治疗取得了长足的发展。曲妥珠单抗联合化疗已成为Her-2阳性乳腺癌患者的标准一线治疗。全文从抗Her-2治疗药物,PI3K/AKT/m

selleck TOR通路中的抑制剂,抗血管生成治疗药物,针对BRCA1/2突变的PARP抑制剂,细胞周期蛋白依赖性激酶4和6(CDK4/6)抑制剂几个方面就当前乳腺癌分子靶向治疗现状作一综述。
Activation of the phosphoinositide 3 kinase(PI3K)/Akt/mammalian target of rapamycin(mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase Ⅰ to Ⅲ trials involving inhibitors of the pathway have been or are being

conducted in solid tumors and breast cancer. Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor(HR)-positive, human epidermal growth factor receptor 2(HER2)-negative breast cancer. In this review, we summarise the efficacy and toxicity findings

from the randomised clinical 通常 trials, with simplified guidelines on the management of potential adverse effects. Education of healthcare professionals and patients is critical for safety and compliance. While there is some clinical evidence of activity of mTOR inhibition in HR-positive and HER2-positive breast cancers, the benefits may be more pronounced in selected subsets rather than in the overall population. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the PI3K/Akt/mTOR(PAM) pathway.
磷脂酰肌醇-3激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(protein kinase Selleck Fasudil B,PKB,又称AKT)-雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)信号通路与细胞的生长、增殖、分化、凋亡、代谢等密切相关,在多种实体肿瘤中已发现该信号通路的异常。近年来,以抑制该通路特定位点的靶向治疗已成为抗肿瘤的研究热点。许多该位点新型抑制剂也已进入淋巴瘤的临床试验中,本文就该通路在淋巴瘤中的活化状态及各个分子靶点抑制剂的研究进展做一综述。
近年来乳腺癌、卵巢癌、胰腺癌等实体瘤的发病率逐年增加,临床上还缺乏有效的治疗药物。作为第1个用于人类癌症疗法的聚腺苷二磷酸核糖聚合酶(PARP)抑制剂,临床前研究表明rucaparib可明显抑制乳腺癌、卵巢癌等实体瘤。临床研究显示rucaparib具有良好的安全性和有效性。主要从rucaparib的药物概况、相关背景、合成路线、临床前研究和临床研究方面进行介绍。
自20世纪90年代起,中国乳腺癌的发病率呈上升趋势。2008年,中国新诊断169 452例浸润性乳腺癌,并且有44 908例乳腺癌相关死亡;21.4%的患者在诊断时为晚期,67.